BDTX
Black Diamond Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
2.20
▲ 0.05 (2.33%)
MARKET · —
Price
Open
2.15
Prev close
2.15
Day high
2.26
Day low
2.15
Volume
652.61K
Market cap
$126.64M
P/E (TTM)
—
52W range
1.60 – 4.94
Trailing performance
Returnvs SPY
1W
+9.41%
+10.8%
1M
+20.11%
+16.4%
3M
-37.75%
-40.8%
6M
-5.15%
-16.2%
YTD
-9.05%
-21.3%
1Y
-15.00%
-35.0%
3Y
-28.25%
-102.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$126.64M
Enterprise value$33.44M
Revenue (TTM)$0
Gross profit$0
EBITDA$-44.35M
Net income$-42.55M
EPS (TTM)$-0.75
Free cash flow$-23.58M
Total cash$110.51M
Total debt$16.97M
Book value / share$1.67
Shares outstanding57.30M
Float52.60M
Short % of float14.67%
Dividend yield—
Beta (5Y)3.29
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.21
PEG ratio—
Price / sales—
Price / book1.32
EV / revenue—
EV / EBITDA-0.75
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-37.21%
Return on assets-19.11%
Debt / equity17.66
Current ratio7.28
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $70.00M | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $22.37M | -$69.68M | -$82.44M | -$91.17M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $22.37M | -$69.68M | -$82.44M | -$91.17M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.17 | +15.0% |
| Mar 2026 | -0.21 | -0.16 | +25.2% |
| Dec 2025 | -0.17 | -0.14 | +19.9% |
| Sep 2025 | -0.23 | -0.15 | +34.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.06 | 6 | $5.56M | 0.0% |
| Next quarter | -0.20 | 6 | $0 | 0.0% |
| Current year | -0.57 | 6 | $5.56M | -92.1% |
| Next year | -1.00 | 6 | $0 | -100.0% |
Analyst targets & ownership
Mean target$10.00
High target$14.00
Low target$8.00
Implied upside354.55%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy2 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders0.65%
Held by institutions72.52%
Institutions holding135
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
373.45K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | BEHBAHANI ALI Director |
STOCK | 8.96K | $14.88K | Direct |
| Jun 18, 26 | RAMAN PRAKASH Director |
STOCK | 7.91K | $13.13K | Direct |
| Mar 20, 26 | BEHBAHANI ALI Director |
STOCK | 6.92K | $14.88K | Direct |
| Mar 20, 26 | RAMAN PRAKASH Director |
STOCK | 6.11K | $13.13K | Direct |
| Dec 12, 25 | BEHBAHANI ALI Director |
STOCK | 5.21K | $14.37K | Direct |
| Dec 12, 25 | RAMAN PRAKASH Director |
STOCK | 4.67K | $12.88K | Direct |
| Sep 19, 25 | BEHBAHANI ALI Director |
STOCK | 4.29K | $14.38K | Direct |
| Sep 19, 25 | RAMAN PRAKASH Director |
STOCK | 3.84K | $12.87K | Direct |
| Jun 20, 25 | BEHBAHANI ALI Director |
STOCK | 6.17K | $14.38K | Direct |
| Jun 20, 25 | RAMAN PRAKASH Director |
STOCK | 5.53K | $12.88K | Direct |
| Mar 21, 25 | BEHBAHANI ALI Director |
STOCK | 7.65K | $14.37K | Direct |
| Mar 21, 25 | RAMAN PRAKASH Director |
STOCK | 6.85K | $12.87K | Direct |
| Mar 19, 25 | BIOTECH GROWTH N.V. Beneficial Owner of more than 10% of a Class of Security |
SELL | 5.78M | $10.71M | Indirect |
| Jan 30, 25 | HATZIS-SCHOCH BRENT Chief Operating Officer |
STOCK | 75.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEHBAHANI ALI |
Director | 4.55M | Stock Award(Grant) |
BIOTECH GROWTH N.V. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
BUCK ELIZABETH PH.D. |
Officer | 170.19K | Stock Award(Grant) |
CAMPBELL SHANNON |
Director | 8.87K | Stock Award(Grant) |
HATZIS-SCHOCH BRENT |
Chief Operating Officer | 83.40K | Stock Award(Grant) |
JONES ERIKA |
Officer | 85.15K | Stock Award(Grant) |
RAMAN PRAKASH |
Director | 45.04K | Stock Award(Grant) |
VELLECA MARK A. |
Chief Executive Officer | 121.52K | Stock Award(Grant) |
VERSANT VENTURE CAPITAL VI, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
YURASOV SERGEY |
Officer | 75.00K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
2.09
+5.41% from price
SMA 20
1.93
+14.51% from price
SMA 50
1.86
+19.00% from price
SMA 100
2.24
-1.90% from price
SMA 200
2.50
-11.50% from price
EMA 12
2.06
+6.93% from price
EMA 26
1.98
+11.33% from price
EMA 50
1.99
+10.39% from price
RSI (14)
67.2
Neutral
MACD (12,26,9)
0.08
Hist 0.03
ATR (14)
0.11
4.77% of price
Realised vol 30D
46.6%
Annualised
Bollinger upper
2.28
20, 2σ
Bollinger lower
1.58
20, 2σ
50 / 200 cross
Death
1.86 vs 2.50
Trend bias
Below 200
-11.50%
Risk profile
Beta vs SPY
1.83
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
46.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-66.9%
Peak to trough
Max drawdown 5Y
-88.0%
Peak to trough
ATR 14
0.11
4.77% of price
Beta (reported)
3.29
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
5.88
Put-heavy session
Put / call open interest
0.37
Positioning, not flow
Max pain
2.50
+13.1% from spot
ATM implied vol
75.8%
Nearest strike to spot
Skew (10% OTM)
+89.8%
Puts bid over calls
Call volume
52
Contracts, this expiry
Put volume
306
Contracts, this expiry
Heaviest call OI
5.00
979 contracts
Heaviest put OI
5.00
501 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Black Diamond: Q2 Earnings Snapshot
Associated Press · 17d ago
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 17d ago
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
MarketBeat · 77d ago
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Zacks · 87d ago
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Zacks · 87d ago
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Zacks · 87d ago
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Zacks · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.